Andrej Bavec (Author), Ivan Krajnc (Author)

Abstract

Izhodišča. Posamezna biološka zdravila, kljub specifičnemu delovanju na določene tarče, pokrivajo zelo širok spekter možnosti uporabe pri zdravljenju različnih bolezni, a se klinična uporaba omejuje na ozke, točno določene indikacije. Najbolj pogosto se uporabljajo po standardnem zdravljenju, ki ni bilo uspešno. Metode. Z raziskavo je bila analizirana uporaba bioloških zdravil v klinični praksi predvsem po indikacijskih področjih na Oddelku za revmatologijo, Oddelku za hematologijo, Oddelku za gastroenterologijo in endoskopijo Klinike za interno medicino, Oddelku za kožne in spolne bolezni ter na Oddelku za ginekološko onkologijo in onkologijo dojk Klinike za ginekologijo in perinatologijo Univerzitetnega kliničnega centra Maribor. Rezultati. V proučevanem obdobju so se biološka zdravila uporabljala pri zdravljenju 195 bolnikov, in sicer vsa trenutno registrirana biološka zdravila, razen abatacepta, anakinre in bevacizumaba. Največ (86) bolnikov se je zdravilo z infliximabom, etanerceptom in adalimumabom na Oddelku za revmatologijo, najpogosteje zaradi revmatoidnega artritisa in ankilozirajočega spondilitisa. 69 bolnic se je s trastuzumabom zdravilo zaradi raka dojke. Na Oddelku za hematologijo so z rituximabom, ibritumomab tiukseatanom, alemtuzumabom in bortezomibom skupaj zdravili 14 bolnikov z ne-Hodgkinovimi limfomi, B-celično kronično limfocitno levkemijo ter plazmocitomom. Z infliximabom je bilo zdravljenih 13 bolnikov s Crohnovo boleznijo ali ulceroznim kolitisom. Zaradi psoriaze s plaki se je z efalizumabom zdravilo 11 in z infliximabom 2 bolnika. Zaključki. S pogostejšo uporabo bioloških zdravil pri bolnikih z različnimi pridruženimi boleznimi lahko pričakujemo razširitev indikacij za zdravljenje. Na osnovi novejših raziskav lahko v klinični praksi pričakujemo uporabo bioloških zdravil v zgodnejšem obdobju bolezni in razvoj novih bioloških zdravil, ki bodo delovala na nove tarče v patogenezi bolezni.

Keywords

biološka zdravila;zdravljenje;revmatoidni artritis;psoriaza;kronična črevesna vnetna bolezen;ne-Hodgkinov limfom;plazmocitom;rak dojke;

Data

Language: Slovenian
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: UM - University of Maribor
Publisher: Slovensko zdravniško društvo
UDC: 615.27
COBISS: 3095359 Link will open in a new window
ISSN: 1318-0347
Parent publication: Zdravniški vestnik
Views: 1229
Downloads: 125
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Use of biological agents at University clinical center Maribor
Secondary abstract: Background. Individual biological agents, despite their specific activity on targets, cover very broad spectrum of possibilities for use in treatment of different diseases. Their clinical use is limited to exact indications with criteria of use. Biological agents are most frequently indicated and used for the treatment of diseases, which were unsuccessfully treated with standard therapy. Methods. Use of biological agents in clinical practice at Department of rheumatology, Department of hematology, Department of gastroenterology at Clinic of internal medicine, Department of skin and venereal diseases and Department of gynecologic and breast oncology at Clinic of gynecology and perinatology was analyzed. Results. Biological agents were used for the treatment of 195 patients. All currently registered biological agents were used except anakinra, abatacept and bevacizumab. Most (86) patients were treated with infliximab, etanercept and adalimumab at the Department of rheumatology, the most frequently because of rheumatoid arthritis and ankylosing spondylitis. 69 patients were treated with trastuzumab because of breast cancer. 14 patients were treated with rituximab, ibritumomab tiukseatan, alemtuzumab and bortezomib at the Department of hematology because of non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia and multiple myeloma. 13 patients with Crohn's disease or ulcerative colitis were treated with infliximab. 11 patients were treated with efalizumab and 2 with infliximab because of psoriasis. Conclusions. Expansion of therapeutic indications is expected with more frequent use of biological agents in patients with different associated diseases. Use of biological agents earlier in the course of disease and development of new biologics, with effect on new targets in pathogenesis of diseases, can be expected on the basis of new researches.
Secondary keywords: Arthritis, Rheumatoid;Revmatoidni artritis;Psoriasis;Psoriaza;Inflammatory Bowel Diseases;Vnetne črevesne bolezni;Lymphoma, Non-Hodgkin;Ne-Hodgkinov limfom;Multiple Myeloma;Multipli mielom;Breast Neoplasms;Dojka, novotvorbe;Biological Therapy;Biološko zdravljenje;
URN: URN:NBN:SI
Type (COBISS): Scientific work
Pages: str. 561-571
Volume: ǂLetn. ǂ77
Issue: ǂšt. ǂ9
Chronology: sep. 2008
ID: 9595055